Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1

Thomas Kryza1, Tashbib Khan1, Scott Lovell2,3

  • 1Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Insights

CUB domain-containing protein 1 (CDCP1) is a cancer target. New probes identified urokinase (uPA) as a key enzyme that cleaves CDCP1, promoting cancer metastasis. Targeting this cleavage may disrupt cancer progression.

Area of Science:

  • Oncology
  • Proteomics
  • Molecular Biology

Background:

  • CUB domain-containing protein 1 (CDCP1) is an oncogenic transmembrane receptor implicated in cancer.
  • Proteolytic cleavage of CDCP1 promotes cancer metastasis through poorly understood mechanisms.

Purpose of the Study:

  • To rapidly identify proteases responsible for CDCP1 cleavage.
  • To investigate the role of CDCP1 proteolysis in cancer metastasis.

Main Methods:

  • Development and application of a substrate-biased activity-based probe (sbABP) for protease identification.
  • In vivo preclinical models to assess metastasis promotion by CDCP1 proteolysis.

Main Results:

  • Identified urokinase (uPA) as the master regulator of CDCP1 proteolysis.
  • Demonstrated that uPA directly cleaves CDCP1 and activates plasmin for further cleavage.
  • Coexpression of uPA and CDCP1 predicts poor disease outcome across multiple cancers.
  • uPA-mediated CDCP1 proteolysis was shown to promote metastasis in vivo.

Conclusions:

  • CDCP1 cleavage is a potential therapeutic target for cancer treatment.
  • sbABP technology is a valuable tool for identifying disease-relevant proteases.
  • uPA-mediated CDCP1 cleavage drives cancer metastasis.

Related Concept Videos